
The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel
This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk.
In this panel:
- Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill
- How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk
- How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two
- Fixed platforms with flexible indications, and when one facility can serve many
- The latest build, buy or partner calls each CEO has made
- Data or instinct: how they decide where to invest next
- The one thing each of them would remove from pharma manufacturing
Be sure to watch to the end for the quickfire round.
Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto
🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026.
Follow ARTO
LinkedIn: https://www.linkedin.com/company/artotalent
Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng
Instagram: https://www.instagram.com/arto.talent
TikTok: https://www.tiktok.com/@artotalent
Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575
Website: https://arto-talent.com/
YouTube: https://www.youtube.com/@artotalent
Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4
The panel :
Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/
Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/
Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/
Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/
Timestamps:
0:00 Intro
0:15 Welcome to the CEO’s Weekly Challenge
0:50 How do you weigh capacity risk against indication risk?
6:50 ten23 health: the science, not the disease
9:06 Do biosimilars take indication risk out?
10:56 Curapath’s ALS customer: from 16 conjugates to four
12:28 Fixed platform, flexible indications
15:31 Fast, flexible capacity: real or a marketing ploy?
23:29 Biosimilars: flexibility or analytical rigour?
26:03 Can one facility serve many indications and be best in class?
28:29 The latest build, buy or partner call
33:35 Data or instinct?
40:34 Quickfire: one thing to remove from pharma manufacturing
#MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery
Hosted on Acast. See acast.com/privacy for more information.
D'autres épisodes de "Making it in Manufacturing"



Ne ratez aucun épisode de “Making it in Manufacturing” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.








